TY - JOUR
T1 - Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
AU - Hendriks, Lizza E. L.
AU - Brouns, Anita J. W. M.
AU - Amini, Mohammad
AU - Uyterlinde, Wilma
AU - Wijsman, Robin
AU - Bussink, Jan
AU - Biesma, Bonne
AU - Oei, S. Bing
AU - Stigt, Jos A.
AU - Bootsma, Gerben P.
AU - Belderbos, Jose S. A.
AU - De Ruysscher, Dirk K. M.
AU - Van den Heuvel, Michel M.
AU - Dingemans, Anne-Marie C.
PY - 2016/11
Y1 - 2016/11
N2 - Objectives: Symptomatic brain metastases (BM) occur frequently after chemoradiotherapy (CRT) for stage III NSCLC. Aim of the current study was to determine whether the specific chemotherapy used in a CRT regimen influences BM development. Materials and methods: Retrospective multicenter study including all consecutive stage III NSCLC who completed CRT. Primary endpoints: symptomatic BM development, whether this was the only site of first relapse. Differences between regimens were assessed with a logistic regression model including known BM risk factors and the specific chemotherapy: concurrent versus sequential (cCRT/sCRT), within cCRT: daily low dose cisplatin (LDC)-cyclic dose polychemotherapy; LDC-(non-)taxane cyclic dose; LDC-polychemotherapy subgroups of >= 50 patients. Results: Between January 2006 and June 2014, 838 patients were eligible (737 cCRT, 101 5CRT). 18.2% developed symptomatic BM, 8.0% had BM as only site of first relapse. BM patients were significantly younger, female, had more advanced N-stage and had adenocarcinoma histology. In both cCRT and sCRT BM were found in 18% (p=0.904). In cyclic dose cCRT (N=346) and LDC (N=391) BM were found in 18.8% and 17.9%, respectively (p=0.757). In 7.2% and 8.7%, respectively, BM were the only site of first relapse (p = 0.463). The chemotherapy used (cCRT versus SCRT) had no influence on BM development, not for all brain relapses nor as only site of first relapse (OR 0.88 (p= 0.669), OR 0.93 (p = 0.855), respectively). LDC versus cyclic dose cCRT was not significantly different: neither for all brain relapses nor as only site of first relapse (OR 0.96 (p = 0.819), OR 1.21 (p= 0.498), respectively).Comparable results were found for LDC versus cyclic dose non-taxane (N = 277) and cyclic dose taxane regimens (N = 69) and for cCRT regimens with >= 50 patients (LDC versus cisplatin/etoposide (N=188), cisplatin/vinorelbin (N= 65), weekly cisplatin/docetaxel (N= 60)). Conclusion: approximately 18% developed symptomatic BM after stage III diagnosis, not dependent on type of chemotherapy regimen used within a CRT treatment.
AB - Objectives: Symptomatic brain metastases (BM) occur frequently after chemoradiotherapy (CRT) for stage III NSCLC. Aim of the current study was to determine whether the specific chemotherapy used in a CRT regimen influences BM development. Materials and methods: Retrospective multicenter study including all consecutive stage III NSCLC who completed CRT. Primary endpoints: symptomatic BM development, whether this was the only site of first relapse. Differences between regimens were assessed with a logistic regression model including known BM risk factors and the specific chemotherapy: concurrent versus sequential (cCRT/sCRT), within cCRT: daily low dose cisplatin (LDC)-cyclic dose polychemotherapy; LDC-(non-)taxane cyclic dose; LDC-polychemotherapy subgroups of >= 50 patients. Results: Between January 2006 and June 2014, 838 patients were eligible (737 cCRT, 101 5CRT). 18.2% developed symptomatic BM, 8.0% had BM as only site of first relapse. BM patients were significantly younger, female, had more advanced N-stage and had adenocarcinoma histology. In both cCRT and sCRT BM were found in 18% (p=0.904). In cyclic dose cCRT (N=346) and LDC (N=391) BM were found in 18.8% and 17.9%, respectively (p=0.757). In 7.2% and 8.7%, respectively, BM were the only site of first relapse (p = 0.463). The chemotherapy used (cCRT versus SCRT) had no influence on BM development, not for all brain relapses nor as only site of first relapse (OR 0.88 (p= 0.669), OR 0.93 (p = 0.855), respectively). LDC versus cyclic dose cCRT was not significantly different: neither for all brain relapses nor as only site of first relapse (OR 0.96 (p = 0.819), OR 1.21 (p= 0.498), respectively).Comparable results were found for LDC versus cyclic dose non-taxane (N = 277) and cyclic dose taxane regimens (N = 69) and for cCRT regimens with >= 50 patients (LDC versus cisplatin/etoposide (N=188), cisplatin/vinorelbin (N= 65), weekly cisplatin/docetaxel (N= 60)). Conclusion: approximately 18% developed symptomatic BM after stage III diagnosis, not dependent on type of chemotherapy regimen used within a CRT treatment.
KW - NSCLC
KW - Stage III
KW - Chemoradiation
KW - Chemotherapy
KW - Symptomatic brain metastases
U2 - 10.1016/j.lungcan.2016.09.008
DO - 10.1016/j.lungcan.2016.09.008
M3 - Article
C2 - 27794410
SN - 0169-5002
VL - 101
SP - 68
EP - 75
JO - Lung Cancer
JF - Lung Cancer
ER -